Technology
GE Healthcare introduced the Discovery NM/CT 670 Pro at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI 2014). Quantitative accuracy in nuclear medicine is enabled by Q.Metrix and Q.AC, GE Healthcare's newest software innovations in nuclear medicine.
June 13, 2014
Feature
June 12, 2014 — Three-dimensional imaging known as 3-D quantitative coronary angiography (3D-QCA) accurately identifies hard-to-see coronary artery lesions that merit further evaluation, according to the IQ-CATEGORIZE Lesions study presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 scientific sessions in Las Vegas.
June 12, 2014
Technology
The U.S. Food and Drug Administration (FDA) today expanded the indicated use for the CoreValve self-expanding transcatheter aortic valve system for patients with severe aortic stenosis who are at high risk for surgery. CoreValve originally gained FDA clearance in January for patients at extreme risk for surgical valve replacement. This new approval is based on groundbreaking data that showed clinical outcomes at one year with the CoreValve system were superior to the current gold standard of open-heart surgery.
June 12, 2014Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News
June 12, 2014 — Philips Healthcare recently introduced Vereos PET/CT, the first digital PET/CT (positron emission tomography/computed tomography) scanner, at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. In addition to Vereos, Philips showcased a selection of molecular imaging solutions designed to deliver high image quality, critical clinical information and greater connectivity.
June 12, 2014Feature
Ischemic heart disease, a narrowing of the arteries supplying blood to the heart, is a leading cause of death throughout the world. A hybrid molecular imaging technique called positron emission tomography and magnetic resonance (PET/MR) imaging, which tells doctors vital information about cardiac and arterial function, has been found to be an effective molecular imaging tool for detecting coronary artery disease (CAD), say researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI).
June 12, 2014News
Capricor Therapeutics Inc. announced the execution of an Exclusive License Agreement with Cedars-Sinai Medical Center for intellectual property (IP) related to the development of exosomes.
June 12, 2014Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024News
Cardiovascular Systems Inc. (CSI) announced that the first patient has been enrolled in its Coronary Orbital Atherectomy System Trial (COAST) trial.
June 12, 2014
Feature
June 11, 2014 — GE Healthcare introduced its Discovery IQ PET/CT (positron emission tomography/computed tomography) system at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. The system enables both high image quality and intelligent quantitation. It is pending 510(k) clearance from the U.S. Food and Drug Administration (FDA) and not available for sale in the United States.
June 11, 2014
News
Medtronic Inc. announced five-year follow-up data demonstrating the safety and performance of the Medtronic 3f Enable Aortic Bioprosthesis — the world's first commercially available sutureless tissue heart valve.
June 11, 2014Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
News
Heart attack and stroke are among the most serious threats to health. But novel research at University of Texas Southwestern Medical Center has linked two major biological processes that occur at the onset of these traumatic events and, ultimately, can lead to protection for the heart.
June 11, 2014
News
Mast Therapeutics Inc. announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188 demonstrated a statistically significant improvement in numerous parameters of heart function, including left ventricular ejection fraction and end-systolic volume, stroke volume and cardiac output.
June 10, 2014Feature
Taking their pick, biomedical researchers can now conduct five different imaging studies in one scan with a state-of-the-art preclinical molecular imaging system that scientists unveiled during the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.
June 10, 2014Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023News
June 10, 2014 — Ariad Pharmaceuticals Inc. and Medinol Ltd. earlier this year initiated two registration trials of Medinol’s NIRsupreme ridaforolimus-eluting coronary stent system incorporating Ariad’s mTOR inhibitor, ridaforolimus. The two NIRsupreme trials are randomized, single-blind, global studies taking place in the United States, Europe, Israel and Canada and will enroll approximately 2,200 patients with coronary artery disease.
June 10, 2014
Feature
June 10, 2014 — A real-time monitoring device that beeps in the presence of high doses of radiation can help reduce patient and interventional cardiologist exposure to radiation during cardiac catheterization, according to results of the RadiCure study presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 scientific sessions in Las Vegas.
June 10, 2014
Feature
June 9, 2014 — After one year, patients treated with orbital atherectomy, a procedure to sand away calcium in the coronary arteries prior to stenting, were less likely to require a repeat procedure to reopen their vessel or suffer a heart attack or death compared to other published trials in patients with heavily calcified arteries. The new results from the ORBIT II study were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 scientific sessions in Las Vegas.
June 09, 2014© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now